Den Europæiske Union - dansk - EMA (European Medicines Agency)

molmed spa - allogen t celler genetisk modificeret med en retroviral vektor kodning for en afkortet form af menneskelige lav affinitet nerve vækstfaktor receptor (Δlngfr) og herpes simplex virus thymidine kinase (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - antineoplastiske midler - zalmoxis er indiceret som supplerende behandling ved haploidentisk hæmatopoietisk stamcelle-transplantation (hsct) hos voksne patienter med højrisiko hæmatologiske maligniteter.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

novo nordisk a/s - somatropin - injektionsvæske, opløsning i cylinderampul - 10 mg/1,5 ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

novo nordisk a/s - somatropin - injektionsvæske, opløsning i cylinderampul - 15 mg/1,5 ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

novo nordisk a/s - somatropin - injektionsvæske, opløsning i cylinderampul - 5 mg/1,5 ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

amgen europe b.v. - talimogen laherparepvec - melanom - antineoplastiske midler - imlygic er indiceret til behandling af voksne med inoperabel modermærkekræft, regionalt eller fjernt metastatisk (stadie iiib, iiic og ivm1a) med ingen ben, hjerne, lunge eller andre visceral sygdom.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan anvendes som monoterapi eller i kombination med methotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopisk - andre dermatologiske præparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - aciclovir - tabletter - 200 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - aciclovir - tabletter - 400 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - valaciclovirhydrochlorid - filmovertrukne tabletter - 500 mg